Nationwide Centralized Manufacturing and Fresh Distribution of TCRαβ/CD19-DepletedGrafts: A Real-World French Experience
Abstract
TCRαβ/CD19 depletion enables mismatched and haploidentical hematopoietic stem cell transplantation (HSCT) without the use of a post-transplant alkylating agent and is particularly relevant for pediatric nonmalignant disorders. However, the complexity of graft engineering limits its availability to specialized centers. Indeed, implementing such a process and obtaining regulatory approval are resource-intensive endeavors that require sufficient patient volume. To address these limitations, we established a centralized platform for the real-time nationwide distribution of fresh TCRα/β/CD19-depleted grafts in France, prioritizing bringing the cells to the patients, rather than the patients to the cells. This study aimed to evaluate the feasibility and challenges of this unique model of centralized, nationwide manufacturing of fresh TCRαβ/CD19-depleted grafts. In this retrospective cohort study (2014 to 2025), after on-site or off-site collections, all haploidentical or mismatched unrelated donors that underwent TCRα/β/CD19 depletion were manufactured at a single academic facility and delivered to nationwide transplant centers. Manufacturing performance, product compliance, logistics (vein-to-vein and delivery times), and early hematologic recovery were analyzed and compared for 10 transplant centers. A total of 55 products were distributed after undergoing TCRα/β/CD19 depletion for Inborn Errors of Immunity (n = 36), DNA repair/bone marrow failure (n = 15), and malignancies (n = 4). Despite significant heterogeneity in starting apheresis materials across different collection centers, manufacturing performance was robust and reliable, with comparable CD34+ recovery, TCRαβ, and CD19 depletion efficacy between on-site and off-site collections. Infused CD34 dose was similar between on-site and off-site apheresis (9.81 × 10(6)/kg versus 9.91 × 10(6)/kg), and TCRα/β doses were <1 × 10(5) in 96% of products. Vein-to-vein time met the <36-h target in 52/55 cases (95%), including the majority of off-site collection and infusion procedures. Delivery time remained within the <6-h specification for all on-site infusions and 14/16 off-site infusions. Early neutrophil and platelet recovery were comparable between groups, with identical 50% recovery times of 15 days post-HSCT. Centralized fresh manufacturing and nationwide distribution of TCRαβ/CD19-depleted grafts are feasible, safe, and logistically robust. This approach represents a valuable intermediate model between local fresh production and centralized cryopreserved manufacturing, particularly in light of the reported limitations of cryopreservation on graft quality and immune effector cell integrity. It may provide a scalable organizational framework for other academic cellular therapy and ATMP platforms.
Related
- The role and evolution of partial splenic embolization over three decades: A multicentric retrospective single cohort study of 90 patients from French nationwide experience
- Survival after hematopoietic cell transplantation in children and adults in four decades of experience: nationwide study
- Cuticulome.org: a centralized database of proteins in arthropod cuticles
- Functional Connectivity Differences Underly Variable Centralized Symptom Relief After Hysterectomy
- Biosynthetic additive manufacturing through mycelium-bacteria consortia
BibTeX
@article{chartral2026nationwide,
title = {{Nationwide Centralized Manufacturing and Fresh Distribution of TCRαβ/CD19-DepletedGrafts: A Real-World French Experience}},
author = {Ugo Chartral and Mony Fahd and Emma Gasperment and Charlotte Calvo and Martin Castelle and Elvira Duchesne and Aurélie Gabrion and Cécile Roudaut and Chloe Mollet and Brigitte Ternaux and Maxime Bouabdelli and Eden Schwartz and Francois Lefrere and Despina Moshous and Vincent Barlogis and Anne-Charlotte Teyssier and Boris Calmels and Clémence Demerlé and Anne-Line Château and Nimrod Buchbinder and Cecile Renard and Marie Ouachée and Cécile Pochon and Virginie Gandemer and Fanny Rialland and Catherine Paillard and Felipe Suarez and Jean-Hughes Dalle and Benedicte Bruno and Elisa Magrin and Bénédicte Neven and Marina Cavazzana-Calvo and Jean-Sebastien Diana},
journal = {Transplantation and Cellular Therapy},
year = {2026},
month = jun,
doi = {10.1016/j.jtct.2026.05.035},
url = {https://hal.science/hal-05684103v1},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Nationwide Centralized Manufacturing and Fresh Distribution of TCRαβ/CD19-DepletedGrafts: A Real-World French Experience
AU - Ugo Chartral
AU - Mony Fahd
AU - Emma Gasperment
AU - Charlotte Calvo
AU - Martin Castelle
AU - Elvira Duchesne
AU - Aurélie Gabrion
AU - Cécile Roudaut
AU - Chloe Mollet
AU - Brigitte Ternaux
AU - Maxime Bouabdelli
AU - Eden Schwartz
AU - Francois Lefrere
AU - Despina Moshous
AU - Vincent Barlogis
AU - Anne-Charlotte Teyssier
AU - Boris Calmels
AU - Clémence Demerlé
AU - Anne-Line Château
AU - Nimrod Buchbinder
AU - Cecile Renard
AU - Marie Ouachée
AU - Cécile Pochon
AU - Virginie Gandemer
AU - Fanny Rialland
AU - Catherine Paillard
AU - Felipe Suarez
AU - Jean-Hughes Dalle
AU - Benedicte Bruno
AU - Elisa Magrin
AU - Bénédicte Neven
AU - Marina Cavazzana-Calvo
AU - Jean-Sebastien Diana
PY - 2026
DA - 2026/06/13
JO - Transplantation and Cellular Therapy
DO - 10.1016/j.jtct.2026.05.035
UR - https://hal.science/hal-05684103v1
AB - TCRαβ/CD19 depletion enables mismatched and haploidentical hematopoietic stem cell transplantation (HSCT) without the use of a post-transplant alkylating agent and is particularly relevant for pediatric nonmalignant disorders. However, the complexity of graft engineering limits its availability to specialized centers. Indeed, implementing such a process and obtaining regulatory approval are resource-intensive endeavors that require sufficient patient volume. To address these limitations, we established a centralized platform for the real-time nationwide distribution of fresh TCRα/β/CD19-depleted grafts in France, prioritizing bringing the cells to the patients, rather than the patients to the cells. This study aimed to evaluate the feasibility and challenges of this unique model of centralized, nationwide manufacturing of fresh TCRαβ/CD19-depleted grafts. In this retrospective cohort study (2014 to 2025), after on-site or off-site collections, all haploidentical or mismatched unrelated donors that underwent TCRα/β/CD19 depletion were manufactured at a single academic facility and delivered to nationwide transplant centers. Manufacturing performance, product compliance, logistics (vein-to-vein and delivery times), and early hematologic recovery were analyzed and compared for 10 transplant centers. A total of 55 products were distributed after undergoing TCRα/β/CD19 depletion for Inborn Errors of Immunity (n = 36), DNA repair/bone marrow failure (n = 15), and malignancies (n = 4). Despite significant heterogeneity in starting apheresis materials across different collection centers, manufacturing performance was robust and reliable, with comparable CD34+ recovery, TCRαβ, and CD19 depletion efficacy between on-site and off-site collections. Infused CD34 dose was similar between on-site and off-site apheresis (9.81 × 10(6)/kg versus 9.91 × 10(6)/kg), and TCRα/β doses were <1 × 10(5) in 96% of products. Vein-to-vein time met the <36-h target in 52/55 cases (95%), including the majority of off-site collection and infusion procedures. Delivery time remained within the <6-h specification for all on-site infusions and 14/16 off-site infusions. Early neutrophil and platelet recovery were comparable between groups, with identical 50% recovery times of 15 days post-HSCT. Centralized fresh manufacturing and nationwide distribution of TCRαβ/CD19-depleted grafts are feasible, safe, and logistically robust. This approach represents a valuable intermediate model between local fresh production and centralized cryopreserved manufacturing, particularly in light of the reported limitations of cryopreservation on graft quality and immune effector cell integrity. It may provide a scalable organizational framework for other academic cellular therapy and ATMP platforms.
SN - 2666-6367
ER -